MDT-AP-2743
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 3
- sex
- M
- new_clusters
- S3
- umap1_2d
- -2.102081412
- umap2_2d
- -7.376931566
- umap1_3d
- -2.585550382
- umap2_3d
- -2.652720012
- umap3_3d
- 6.299679793
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- TNFA_SIGNALING_VIA_NFKB+0.570
- INFLAMMATORY_RESPONSE+0.560
- INTERFERON_GAMMA_RESPONSE+0.500
- KRAS_SIGNALING_UP+0.500
- ANGIOGENESIS+0.470
- IL6_JAK_STAT3_SIGNALING+0.470
- COMPLEMENT+0.440
- INTERFERON_ALPHA_RESPONSE+0.440
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.600
- DNA_REPAIR-0.510
- MYC_TARGETS_V1-0.510
- G2M_CHECKPOINT-0.500
- OXIDATIVE_PHOSPHORYLATION-0.440
- MITOTIC_SPINDLE-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- MTORC1_SIGNALING-0.330
- PEROXISOME-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-38-7271-01A-11R-2039-07 | — | cohortMD2 | 0.951 |
| 2 | BS_1KYGSMA7 | low-grade glioma | — | 0.941 |
| 3 | MDT-AP-3277 | Med | Medulloblastoma | 0.935 |
| 4 | SRR1342045 | GTEX | — | 0.933 |
| 5 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.933 |
| 6 | TCGA-CX-7085-01A-21R-2016-07 | — | — | 0.931 |
| 7 | MDT-AP-2638 | Med | Medulloblastoma | 0.931 |
| 8 | TCGA-55-8091-01A-11R-2241-07 | — | cohortA1 | 0.929 |
| 9 | ERR2208937 | — | — | 0.926 |
| 10 | BS_3H71BH6Q | Ganglioglioma | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| HYPOXIA | 0.380 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |